Professor Martine Bagot and Professor Armand Bensussan are rewarded for their research on the development of a targeted therapy, lacutamab, a monoclonal antibody targeting the tumor antigen KIR3DL2 for the treatment of patients with advanced, refractory and relapsed T cell lymphomas, particularly erythrodermic cutaneous T cell lymphomas. The Galien Prize here rewards two decades of research.